 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LABETALOL increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-LABETALOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LABETALOL increase the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-LABETALOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LABETALOL increase the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LABETALOL increase the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LABETALOL increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"LABETALOL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LABETALOL: clinical_pharmacology: Hemodynamic effects are variable, with small, nonsignificant changes in cardiac output seen in some studies but not others, and small decreases in total [0m
[31mperipheral resistance. Elevated plasma renins are reduced. Doses of labetalol HCl that controlled hypertension did not affect renal function in mildly to severely hypertensive patients with normal [0m
[31mrenal function. Due to the alpha [0m[1;31m1[0m[31m -receptor blocking activity of labetalol HCl, blood pressure is lowered more in the standing than in the supine position, and symptoms of postural hypotension [0m[1;31m([0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m, [0m
[31mincluding rare instances of syncope, can occur. Following oral administration, when postural hypotension has occurred, it has been transient and is uncommon when the recommended starting dose and [0m
[31mtitration increments are closely followed [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Symptomatic postural hypotension is most likely to occur [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours after a dose, especially following the use of large [0m
[31minitial doses or upon large changes in dose. LABETALOL: clinical_pharmacology: The peak effects of single oral doses of labetalol HCl occur within [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours. The duration of effect depends upon [0m
[31mdose, lasting at least [0m[1;31m8[0m[31m hours following single oral doses of [0m[1;31m100[0m[31m mg and more than [0m[1;31m12[0m[31m hours following single oral doses of [0m[1;31m300[0m[31m mg. The maximum, steady-state blood pressure response upon oral, [0m
[31mtwice-a-day dosing occurs within [0m[1;31m24[0m[31m to [0m[1;31m72[0m[31m hours. The antihypertensive effect of labetalol has a linear correlation with the logarithm of labetalol plasma concentration, and there is also a linear [0m
[31mcorrelation between the reduction in exercise-induced tachycardia occurring at [0m[1;31m2[0m[31m hours after oral administration of labetalol HCl and the logarithm of the plasma concentration. About [0m[1;31m70[0m[31m% of the [0m
[31mmaximum beta-blocking effect is present for [0m[1;31m5[0m[31m hours after the administration of a single oral dose of [0m[1;31m400[0m[31m mg with suggestion that about [0m[1;31m40[0m[31m% remains at [0m[1;31m8[0m[31m hours. LABETALOL: clinical_pharmacology: The [0m
[31mantianginal efficacy of labetalol HCl has not been studied. In [0m[1;31m37[0m[31m patients with hypertension and coronary artery disease, labetalol HCl did not increase the incidence or severity of angina attacks. [0m
[31mExacerbation of angina and, in some cases, myocardial infarction and ventricular dysrhythmias have been reported after abrupt discontinuation of therapy with beta-adrenergic blocking agents in [0m
[31mpatients with coronary artery disease. Abrupt withdrawal of these agents in patients without coronary artery disease has resulted in transient symptoms, including tremulousness, sweating, palpitation,[0m
[31mheadache, and malaise. Several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta receptors. Although [0m
[31mbeta-adrenergic receptor blockade is useful in the treatment of angina and hypertension, there are also situations in which sympathetic stimulation is vital. LABETALOL: clinical_pharmacology: For [0m
[31mexample, in patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. Beta-adrenergic blockade may worsen A-V block by preventing the necessary facilitating[0m
[31meffects of sympathetic activity on conduction. Beta [0m[1;31m2[0m[31m -adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients [0m
[31msubject to bronchospasm, and it may also interfere with exogenous bronchodilators in such patients. Pharmacokinetics and Metabolism: Labetalol HCl is completely absorbed from the gastrointestinal [0m
[31mtract with peak plasma levels occurring [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m hours after oral administration. The relative bioavailability of labetalol HCl tablets compared to an oral solution is [0m[1;31m100[0m[31m%. The absolute bioavailability[0m
[1;31m([0m[31mfraction of drug reaching systemic circulation[0m[1;31m)[0m[31m of labetalol when compared to an IV infusion is [0m[1;31m25[0m[31m%; this is due to extensive [0m[31m"first-pass"[0m[31m metabolism. LABETALOL: clinical_pharmacology: Despite [0m
[31m"first-pass"[0m[31m metabolism, there is a linear relationship between oral doses of [0m[1;31m100[0m[31m to [0m[1;31m3[0m[31m,[0m[1;31m000[0m[31m mg and peak plasma levels. The absolute bioavailability of labetalol is increased when administered with [0m
[31mfood. The plasma half-life of labetalol following oral administration is about [0m[1;31m6[0m[31m to [0m[1;31m8[0m[31m hours. Steady-state plasma levels of labetalol during repetitive dosing are reached by about the third day of [0m
[31mdosing. In patients with decreased hepatic or renal function, the elimination half-life of labetalol is not altered; however, the relative bioavailability in hepatically impaired patients is increased[0m
[31mdue to decreased [0m[31m"first-pass"[0m[31m metabolism. The metabolism of labetalol is mainly through conjugation to glucuronide metabolites. These metabolites are present in plasma and are excreted in the urine [0m
[31mand, via the bile, into the feces.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: precautions: Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater [0m
[31mthan the normal antiasthmatic dose of beta-agonist bronchodilator drugs may be required. Cimetidine has been shown to increase the bioavailability of labetalol HCl. Since this could be explained [0m
[31meither by enhanced absorption or by an alteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients. [0m
[31mSynergism has been shown between halothane anesthesia and intravenously administered labetalol HCl. LABETALOL: precautions: During controlled hypotensive anesthesia using labetalol HCl in association [0m
[31mwith halothane, high concentrations [0m[1;31m([0m[1;31m3[0m[31m% or above[0m[1;31m)[0m[31m of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac [0m
[31moutput and an increase in central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol HCl. Labetalol HCl blunts the reflex tachycardia produced by [0m
[31mnitroglycerin without preventing its hypotensive effect. If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur. Care should be [0m
[31mtaken if labetalol is used concomitantly with calcium antagonists of the verapamil type. Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. [0m
[31mLABETALOL: precautions: comitant use can increase the risk of bradycardia. Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a [0m
[31mvariety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat [0m
[31mallergic reaction. Drug & OR Laboratory Test Interactions The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, [0m
[31mnormetanephrine, and vanillylmandelic acid when measured by fluorimetric or photometric methods. In screening patients suspected of having a pheochromocytoma and being treated with labetalol HCl, a [0m
[31mspecific method, such as a high performance liquid chromatographic assay with solid phase extraction [0m[1;31m([0m[31me.g. LABETALOL: precautions: J Chromatogr [0m[1;31m385:241[0m[31m,[0m[1;31m1987[0m[1;31m)[0m[31m should be employed in determining levels [0m
[31mof catecholamines. Labetalol HCl has also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods [0m
[31mToxi-Lab A ® [0m[1;31m([0m[31mthin-layer chromatographic assay[0m[1;31m)[0m[31m and Emit-d.a.u ® [0m[1;31m([0m[31mradioenzymatic assay[0m[1;31m)[0m[31m. When patients being treated with labetalol have a positive urine test for amphetamine using these techniques, [0m
[31mconfirmation should be made by using more specific methods, such as a gas chromatographic-mass spectrometer technique. Carcinogenesis & Mutagenesis & Impairment Of Fertility Long-term oral dosing [0m
[31mstudies with labetalol HCl for [0m[1;31m18[0m[31m months in mice and for [0m[1;31m2[0m[31m years in rats showed no evidence of carcinogenesis. LABETALOL: precautions: Studies with labetalol HCl using dominant lethal assays in rats [0m
[31mand mice and exposing microorganisms according to modified Ames tests showed no evidence of mutagenesis. Pregnancy Teratogenic Effects: Pregnancy Category C: Teratogenic studies were performed with [0m
[31mlabetalol in rats and rabbits at oral doses up to approximately six and four times the maximum recommended human dose [0m[1;31m([0m[31mMRHD[0m[1;31m)[0m[31m, respectively. No reproducible evidence of fetal malformations was [0m
[31mobserved. Increased fetal resorptions were seen in both species at doses approximating the MRHD. A teratology study performed with labetalol in rabbits at IV doses up to [0m[1;31m1.7[0m[31m times the MRHD revealed no[0m
[31mevidence of drug related harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Labetalol should be used during pregnancy only if the potential benefit justifies the [0m
[31mpotential risk to the fetus.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects are mild and transient and occur early in the course of treatment. In controlled clinical trials of [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m months' [0m
[31mduration, discontinuation of labetalol hydrochloride tablets due to one or more adverse effects was required in [0m[1;31m7[0m[31m% of all patients. In these same trials, other agents with solely beta-blocking [0m
[31mactivity used in the control groups led to discontinuation in [0m[1;31m8[0m[31m% to [0m[1;31m10[0m[31m% of patients, and a centrally acting alpha-agonist led to discontinuation in [0m[1;31m30[0m[31m% of patients. The incidence rates of adverse [0m
[31mreactions listed in the following table were derived from multicenter, controlled clinical trials comparing labetalol HCl, placebo, metoprolol, and propranolol over treatment periods of [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m [0m
[31mmonths. Where the frequency of adverse effects for labetalol HCl and placebo is similar, causal relationship is uncertain. The rates are based on adverse reactions considered probably drug related by [0m
[31mthe investigator. LABETALOL: adverse_reactions: If all reports are considered, the rates are somewhat higher [0m[1;31m([0m[31me.g., dizziness, [0m[1;31m20[0m[31m%; nausea, [0m[1;31m14[0m[31m%; fatigue, [0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m, but the overall conclusions are [0m
[31munchanged. LABETALOL: adverse_reactions: Labetalol HCI Placebo Propranolol Metoprolol [0m[1;31m([0m[31mn = [0m[1;31m227[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m98[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m84[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m49[0m[1;31m)[0m[31m % % % % Body as a whole Fatigue [0m[1;31m5[0m[31m [0m[1;31m0[0m[31m [0m[1;31m12[0m[31m [0m[1;31m12[0m[31m Asthenia [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Headache [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m
[31mGastrointestinal Nausea [0m[1;31m6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Vomiting <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Dyspepsia [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Abdominal pain [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Diarrhea <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Taste distortion [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Central and peripheral nervous systems Dizziness [0m[1;31m11[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m
[31mParesthesia <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Drowsiness <[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m Autonomic nervous system Nasal stuffiness [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m LABETALOL: adverse_reactions: [0m[1;31m0[0m[31m Ejaculation failure [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Impotence [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m Increased sweating <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m
[31mCardiovascular Edema [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Postural hypotension [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Bradycardia [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m Respiratory Dyspnea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Skin Rash [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Special senses Visionabnormality [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Vertigo [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m The adverse [0m
[31meffects were reported spontaneously and are representative of the incidence of adverse effects that may be observed in a properly selected hypertensive patient population, i.e., a group excluding [0m
[31mpatients with bronchospastic disease, overt congestive heart failure, or other contraindications to beta-blocker therapy. Clinical trials also included studies utilizing daily doses up to [0m[1;31m2[0m[31m,[0m[1;31m400[0m[31m mg in [0m
[31mmore severely hypertensive patients. LABETALOL: adverse_reactions: Certain of the side effects increased with increasing dose, as shown in the following table that depicts the entire U.S. therapeutic [0m
[31mtrials data base for adverse reactions that are clearly or possibly dose related. LABETALOL: adverse_reactions: Labetalol HCl Daily Dose [0m[1;31m([0m[31mmg[0m[1;31m)[0m[31m [0m[1;31m200[0m[31m [0m[1;31m300[0m[31m [0m[1;31m400[0m[31m [0m[1;31m600[0m[31m [0m[1;31m800[0m[31m [0m[1;31m900[0m[31m [0m[1;31m1[0m[31m,[0m[1;31m200[0m[31m [0m[1;31m1[0m[31m,[0m[1;31m600[0m[31m [0m[1;31m2[0m[31m,[0m[1;31m400[0m[31m Number of [0m
[31mpatients [0m[1;31m522[0m[31m [0m[1;31m181[0m[31m [0m[1;31m606[0m[31m [0m[1;31m608[0m[31m [0m[1;31m503[0m[31m [0m[1;31m117[0m[31m [0m[1;31m411[0m[31m [0m[1;31m242[0m[31m [0m[1;31m175[0m[31m Dizziness [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m [0m[1;31m5[0m[31m [0m[1;31m1[0m[31m [0m[1;31m9[0m[31m [0m[1;31m13[0m[31m [0m[1;31m16[0m[31m Fatigue [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m10[0m[31m Nausea <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m7[0m[31m [0m[1;31m11[0m[31m [0m[1;31m19[0m[31m Vomiting [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m <[0m[1;31m1[0m[31m <[0m[1;31m1[0m[31m <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m Dyspepsia [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m
[31mParesthesia [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m Nasal stuffiness [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m LABETALOL: adverse_reactions: [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m [0m[1;31m6[0m[31m Ejaculation failure [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m5[0m[31m Impotence [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Edema [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m In addition, a [0m
[31mnumber of other less common adverse events have been reported: Body as a Whole: Fever. Cardiovascular: Hypotension, and rarely, syncope, bradycardia, heart block. Central and Peripheral Nervous [0m
[31mSystems: Paresthesia, most frequently described as scalp tingling. In most cases, it was mild and transient and usually occurred at the beginning of treatment. Collagen Disorders: Systemic lupus [0m
[31merythematosus, positive antinuclear factor. Eyes: Dry eyes. Immunological System: Antimitochondrial antibodies. LABETALOL: adverse_reactions: Liver and Biliary System: Hepatic necrosis, hepatitis, [0m
[31mcholestatic jaundice, elevated liver function tests. Musculoskeletal System: Muscle cramps, toxic myopathy. Respiratory System: Bronchospasm. Skin and Appendages: Rashes of various types, such as [0m
[31mgeneralized maculopapular, lichenoid, urticarial, bullous lichen planus, psoriaform, and facial erythema; Peyronie's disease; reversible alopecia. Urinary System: Difficulty in micturition, including [0m
[31macute urinary bladder retention. Hypersensitivity: Rare reports of hypersensitivity [0m[1;31m([0m[31me.g., rash, urticaria, pruritus, angioedema, dyspnea[0m[1;31m)[0m[31m and anaphylactoid reactions. Following approval for marketing[0m
[31min the United Kingdom, a monitored release survey involving approximately [0m[1;31m6[0m[31m,[0m[1;31m800[0m[31m patients was conducted for further safety and efficacy evaluation of this product. LABETALOL: adverse_reactions: Results[0m
[31mof this survey indicate that the type, severity, and incidence of adverse effects were comparable to those cited above. Potential Adverse Effects: In addition, other adverse effects not listed above [0m
[31mhave been reported with other beta-adrenergic blocking agents. Central Nervous System: Reversible mental depression progressing to catatonia, an acute reversible syndrome characterized by [0m
[31mdisorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on psychometrics. Cardiovascular: Intensification of A-V block [0m[1;31m([0m[31msee[0m
[31mCONTRAINDICATIONS [0m[1;31m)[0m[31m. Allergic: Fever combined with aching and sore throat, laryngospasm, respiratory distress. Hematologic: Agranulocytosis, thrombocytopenic or nonthrombocytopenic purpura. [0m
[31mGastrointestinal: Mesenteric artery thrombosis, ischemic colitis. LABETALOL: adverse_reactions: The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with [0m
[31mlabetalol HCl. Clinical Laboratory Tests: There have been reversible increases of serum transaminases in [0m[1;31m4[0m[31m% of patients treated with labetalol HCl and tested and, more rarely, reversible increases in [0m
[31mblood urea.         [0m
[31mSOURCE:LABETALOL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Labetalol has been associated with reports of hypersensitivity reactions, which include rash, urticaria, pruritus, angioedema, and dyspnea. This indicates that labetalol can increase the risk [0m
[32mof angioedema, although it is considered a rare adverse reaction.[0m

[32mSOURCE: LABETALOL label[0m
[32mEXTRACT_START_END: Hypersensitivity: Rare reports of hypersensitivity[0m[32m...[0m[32m angioedema, dyspnea[0m[1;32m)[0m[32m and anaphylactoid reactions.[0m
*[1m([0morchestrator-angioedema-LABETALOL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Labetalol has been associated with reports of hypersensitivity [0m
[34mreactions, which include rash, urticaria, pruritus, angioedema, and dyspnea. This indicates that labetalol can increase the risk of angioedema, although it is considered a rare adverse reaction.[0m

[34mSOURCE: LABETALOL label[0m
[34mEXTRACT_START_END: Hypersensitivity: Rare reports of hypersensitivity[0m[34m...[0m[34m angioedema, dyspnea[0m[1;34m)[0m[34m and anaphylactoid reactions.[0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-LABETALOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does LABETALOL increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether LABETALOL increases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that LABETALOL has been associated with reports of hypersensitivity reactions, which include angioedema, although it is considered a rare adverse reaction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Labetalol can increase the risk of angioedema, but this is considered a rare adverse reaction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-LABETALOL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does LABETALOL increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether LABETALOL increases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that LABETALOL has been associated with reports of hypersensitivity reactions, which include angioedema, although it is considered a rare adverse reaction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Labetalol can increase the risk of angioedema, but this is considered a rare adverse reaction."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does LABETALOL increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether LABETALOL increases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that LABETALOL has been associated with reports of hypersensitivity reactions, which include angioedema, although it is considered a rare adverse reaction.[0m
[31m        -----[0m
[31m        Final answer: Labetalol can increase the risk of angioedema, but this is considered a rare adverse reaction.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-LABETALOL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-LABETALOL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-LABETALOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-LABETALOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mLabetalol can increase the risk of angioedema, but this is considered a rare adverse reaction.[0m
